Medtronic, Inc. Launches AneuRx AAAdvantage(R) Stent Graft on New Xcelerant(R) Hydro Delivery System in U.S. for Minimally Invasive Treatment of Abdominal Aortic Aneurysms

MINNEAPOLIS--(BUSINESS WIRE)--Continuing its record of innovation in endovascular therapies for aortic aneurysms, Medtronic, Inc. (NYSE: MDT), today announced the U.S. market launch of the AneuRx AAAdvantage® Stent Graft on the new Xcelerant® Hydro Delivery System, which features a hydrophilic coating designed to aid navigation of the device through tight and tortuous arteries by reducing friction with the artery wall. In addition, Medtronic has also received approval from the U.S. Food and Drug Administration to introduce its latest generation of packaging materials for the launch of this product.